These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32427006)

  • 1. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population.
    Pilon D; Ding Z; Muser E; Obando C; Voelker J; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P
    Curr Med Res Opin; 2020 Aug; 36(8):1285-1294. PubMed ID: 32427006
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
    Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
    J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.
    Manceur AM; Ding Z; Muser E; Obando C; Voelker J; Pilon D; Kinkead F; Lafeuille MH; Lefebvre P
    J Med Econ; 2020 Oct; 23(10):1092-1101. PubMed ID: 32609019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
    Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
    Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.
    Bickston SJ; Waters HC; Dabbous O; Tang BI; Rahman M
    J Manag Care Pharm; 2008 May; 14(4):352-62. PubMed ID: 18500913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mental Health Costs of Inflammatory Bowel Diseases.
    Szigethy E; Murphy SM; Ehrlich OG; Engel-Nitz NM; Heller CA; Henrichsen K; Lawton R; Meadows P; Allen JI
    Inflamm Bowel Dis; 2021 Jan; 27(1):40-48. PubMed ID: 32095835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.
    Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States.
    Blaiss MS; Meadows JA; Yu S; Robison DR; Hass SL; Norrett KE; Guerin A; Latremouille-Viau D; Tilles SA
    J Manag Care Spec Pharm; 2021 Apr; 27(4):516-527. PubMed ID: 33470880
    [No Abstract]   [Full Text] [Related]  

  • 9. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
    Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
    Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care expenditures in ulcerative colitis: the perspective of a self-insured employer.
    Hillson E; Dybicz S; Waters HC; Stuart B; Schaneman J; Dabbous O; Erwin WG; Kersh A; Broussard D
    J Occup Environ Med; 2008 Aug; 50(8):969-77. PubMed ID: 18695456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
    Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
    J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
    Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
    J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
    [No Abstract]   [Full Text] [Related]  

  • 16. Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: A database study.
    Aldeguer X; Sicras-Mainar A
    Gastroenterol Hepatol; 2016 Jan; 39(1):9-19. PubMed ID: 26211705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.
    Kappelman MD; Rifas-Shiman SL; Porter CQ; Ollendorf DA; Sandler RS; Galanko JA; Finkelstein JA
    Gastroenterology; 2008 Dec; 135(6):1907-13. PubMed ID: 18854185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.